logo
Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

Yahoo12-05-2025

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and is poised for future drug approvals. This advanced testing protocol aims to provide deeper insights into the molecular characteristics of NSQ NSCLC, facilitating more personalized and effective treatment strategies.
Approximately 50% of NSQ NSCLCs lack a targetable gene driver mutation, making MET protein expression an important additional personalized target. Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in cell proliferation, invasion, and survival, making it a vital biomarker for targeted therapies.
"To our knowledge, Caris is the only lab in the US that has historically and is currently offering the MET (SP44) RxDx assay for NSQ NSCLC," said Caris President David Spetzler, MS, PhD, MBA. "With MET IHC testing already in place, we are poised and ready to provide a detailed molecular profile to inform targeted therapies and future drug development approvals."
Key Highlights of MET IHC Testing:Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors.
Identification of Actionable Targets: The MET IHC testing helps identify overexpression of the MET protein, which is associated with poor prognosis and can be targeted by specific therapies.
Enhanced Treatment Personalization: By understanding the molecular makeup of NSQ NSCLC tumors, oncologists can tailor treatment plans to the individual needs of patients, potentially improving outcomes and quality of life.
Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific research. Deployment of MET IHC testing for NSQ NSCLC patients underscores this commitment and highlights Caris' dedication to improving patient care and outcomes.
Caris' comprehensive molecular profile testing includes MI Cancer Seek® and Caris Assure®. Caris received FDA approval in November of 2024 for MI Cancer Seek®, a tissue-based assay which is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Caris Assure® is a powerful blood-based assay that uniquely identifies somatic tumor, incidental clonal hematopoiesis and incidental germline variants by sequencing both plasma and buffy coat through a WTS and WES-based assay.
About Caris Life SciencesCaris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.
Caris Life Sciences Media: Corporate CommunicationsCorpComm@CarisLS.com214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-provides-met-immunohistochemistry-testing-as-standard-of-care-for-non-squamous-non-small-cell-lung-cancer-patients-302451928.html
SOURCE Caris Life Sciences

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

It's Official! California's Snacking Hour is 3:00 PM Real California Milk Celebrates with Snack Ideas to Curb Summer Cravings
It's Official! California's Snacking Hour is 3:00 PM Real California Milk Celebrates with Snack Ideas to Curb Summer Cravings

Yahoo

time26 minutes ago

  • Yahoo

It's Official! California's Snacking Hour is 3:00 PM Real California Milk Celebrates with Snack Ideas to Curb Summer Cravings

TRACY, Calif., June 9, 2025 /PRNewswire/ -- Afternoon snacking is becoming more prevalent than ever, with 35% of consumers now snacking between 2 and 5 p.m.* For most, the dreaded afternoon slump typically hits at 3 p.m. To help consumers snap out of the slump, Real California Milk is declaring 3:00 p.m. the official snacking hour for Californians! When it comes to delicious, satisfying snacks, nothing beats California dairy – but with so many options, how to choose? The culinary experts at Real California Milk created a snacking guide to assist Golden State denizens in selecting the perfect snack. From retro to healthy to indulgent, take this journey to identify the best snack for every craving this summer. "California dairy foods are not only delicious and on-trend but packed with the essential nutrients you look for when choosing an afternoon snack," said Jennifer Giambroni, VP of Communications at Real California Milk. "There's an option for everyone and every occasion." According to California dietitian Patricia Bannan, MS, RDN, "that afternoon energy dip is real – and it's not just in your head. Our circadian rhythms naturally slow in the afternoon and many people feel a drop in energy or focus a few hours after lunch. A good snack can turn your whole afternoon around—especially when it tastes great and helps you feel more focused and energized. The right dairy-based snack can satisfy your cravings and give your brain and body the fuel they need to power through the rest of the day." Bannan also suggests pairing your dairy-based snack selection with a fruit or vegetable to help boost fiber and overall nutrient density. For more afternoon snacking inspiration, visit About Real California Milk/California Milk Advisory BoardThe California Milk Advisory Board (CMAB), an instrumentality of the California Department of Food and Agriculture, is funded by the state's dairy farm families who lead the nation in sustainable dairy farming practices. With a vision to nourish the world with the wholesome goodness of Real California Milk, the CMAB's programs focus on increasing demand for California's sustainable dairy products in the state, across the U.S. and around the world. Connect with the CMAB at Facebook, YouTube, Tik Tok, Instagram, X and Pinterest. *Snac International 2025 State of the Industry Report View original content to download multimedia: SOURCE Real California Milk Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing

Yahoo

time33 minutes ago

  • Yahoo

Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing

NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Yahoo

time33 minutes ago

  • Yahoo

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store